Organization Overview
Alternative names
aldesleukin (Proleukin) (1 trial)
allogeneic cd19 car-t cells (1 trial)
cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t-lymphocytes (1 trial)
cyclophosphamide (cytoxan) (3 trials)
cytarabine (cytosar-u) (1 trial)
Bone Marrow Neoplasms (Phase 2)
Brain Neoplasms (Phase 1)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Germinoma (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 1)
Hematologic Neoplasms (Phase 2)
Leukemia (Phase 1)
Leukemia, Biphenotypic, Acute (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Lymphoid (Phase 1)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 2)
Lymphoma, Non-Hodgkin (Phase 1)
Lymphoproliferative Disorders (Phase 1)
Melanoma (Phase 2)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 1)
Myeloproliferative Disorders (Phase 1)
Neoplasm, Residual (Phase 1)
Neoplasms (Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neoplasms, Plasma Cell (Phase 2)
Osteosarcoma (Phase 1)
Ovarian Neoplasms (Phase 2)
Preleukemia (Phase 1)
Sarcoma (Phase 3)
Seminoma (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Teratoma (Phase 2)
Testicular Neoplasms (Phase 2)
Thymoma (Phase 1)